Cross-disorder and disease-specific pathways in dementia revealed by single-cell genomics

Cell. 2024 Oct 3;187(20):5753-5774.e28. doi: 10.1016/j.cell.2024.08.019. Epub 2024 Sep 11.

Abstract

The development of successful therapeutics for dementias requires an understanding of their shared and distinct molecular features in the human brain. We performed single-nuclear RNA-seq and ATAC-seq in Alzheimer's disease (AD), frontotemporal dementia (FTD), and progressive supranuclear palsy (PSP), analyzing 41 participants and ∼1 million cells (RNA + ATAC) from three brain regions varying in vulnerability and pathological burden. We identify 32 shared, disease-associated cell types and 14 that are disease specific. Disease-specific cell states represent glial-immune mechanisms and selective neuronal vulnerability impacting layer 5 intratelencephalic neurons in AD, layer 2/3 intratelencephalic neurons in FTD, and layer 5/6 near-projection neurons in PSP. We identify disease-associated gene regulatory networks and cells impacted by causal genetic risk, which differ by disorder. These data illustrate the heterogeneous spectrum of glial and neuronal compositional and gene expression alterations in different dementias and identify therapeutic targets by revealing shared and disease-specific cell states.

Keywords: KCNH7; MAFG; NFE2L1; NLGN1; OPCML; PDE1C; drug discovery; functional genomics; multi-omics; tauopathy.

MeSH terms

  • Aged
  • Aged, 80 and over
  • Alzheimer Disease* / genetics
  • Alzheimer Disease* / metabolism
  • Alzheimer Disease* / pathology
  • Brain / metabolism
  • Brain / pathology
  • Dementia / genetics
  • Dementia / metabolism
  • Dementia / pathology
  • Female
  • Frontotemporal Dementia* / genetics
  • Frontotemporal Dementia* / metabolism
  • Frontotemporal Dementia* / pathology
  • Gene Regulatory Networks*
  • Genomics* / methods
  • Humans
  • Male
  • Middle Aged
  • Neuroglia / metabolism
  • Neuroglia / pathology
  • Neurons* / metabolism
  • Neurons* / pathology
  • RNA-Seq
  • Single-Cell Analysis*
  • Supranuclear Palsy, Progressive* / genetics
  • Supranuclear Palsy, Progressive* / metabolism
  • Supranuclear Palsy, Progressive* / pathology